Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TCRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTScan Therapeutics VP of Finance resigns; CFO assumes accounting officer duties
Filed April 2, 2026 · Period ending March 31, 2026 · ~1 min read
Key Changes
-
medium
Leiden Dworak resigned as VP of Finance and principal accounting officer effective April 10, 2026, with no reported disagreements on operations or policies.
Item 5.02 verify on EDGAR → -
medium
CFO Jason Amello appointed to also serve as principal accounting officer starting April 10, with no additional compensation for the expanded role.
Item 5.02 verify on EDGAR →
Summary
TScan Therapeutics disclosed a routine leadership transition in its finance organization. VP of Finance Leiden Dworak resigned effective April 10, 2026, and the company stated there were no disagreements related to operations, policies, or practices. CFO Jason Amello will absorb the principal accounting officer responsibilities without additional pay, consolidating financial oversight under existing leadership.
For retail investors, this appears to be a standard organizational change rather than a red flag. The absence of reported disagreements and the seamless transition to the existing CFO suggests normal turnover. However, investors should watch the Q1 2026 earnings call and subsequent filings to ensure financial reporting quality remains consistent under the consolidated structure and to confirm no underlying issues prompted the departure.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify